Benoît Brilland
@benoitbrilland.bsky.social
MD, PhD | Nephrology, Immunology | #ANCA #glomerulonephritis #transcriptomics | @maineanjoureg.bsky.social
Hi! Thanks for pinging. I think there is no one-size-fits-all answer. Would consider:
- risk of relapse: GPA/PR3-AAV? ANCA titer overtime? eGFR (= « tolerability » of a future relapse)? Already relapsed? CD19 not that important imo
- risk of SAE, esp. infections (frailty, comorbidities, IgG levels)
- risk of relapse: GPA/PR3-AAV? ANCA titer overtime? eGFR (= « tolerability » of a future relapse)? Already relapsed? CD19 not that important imo
- risk of SAE, esp. infections (frailty, comorbidities, IgG levels)
December 3, 2024 at 1:02 AM
Hi! Thanks for pinging. I think there is no one-size-fits-all answer. Would consider:
- risk of relapse: GPA/PR3-AAV? ANCA titer overtime? eGFR (= « tolerability » of a future relapse)? Already relapsed? CD19 not that important imo
- risk of SAE, esp. infections (frailty, comorbidities, IgG levels)
- risk of relapse: GPA/PR3-AAV? ANCA titer overtime? eGFR (= « tolerability » of a future relapse)? Already relapsed? CD19 not that important imo
- risk of SAE, esp. infections (frailty, comorbidities, IgG levels)